Track 1: Production and Economics

• Joanne T. Beck, Ph.D., Plant Manager, Abbott Bioresearch Center
• Wolfgang Berthold, Ph.D., Chief Technical Officer, Biogen Idec
• William P. Botha, Director of Manufacturing, Baxter Healthcare Corporation
• Andrew Cockshott, Ph.D., Manager, Manufacturing Science and Technology, Eli Lilly and Co.
• Jon T. Conary, Ph.D., Senior Director, Manufacturing, Human Genome Sciences, Inc.
• Howard L. Levine, Ph.D., President, BioProcess Technology Consultants, Inc.
• Duncan Low, Ph.D., Scientific Executive Director, Process Development, Amgen, Inc.
• Rhona M. O'Leary, Ph.D., Director, BioProcess Development, Genentech, Inc.

Track 2: Scaling up from Bench through Commercialization

• Jeffrey C. Baker, Ph.D., Senior Research Advisor, Manufacturing Sciences and Technology, Eli Lilly and Co.
• Roger A. Hart, Ph.D., Scientific Director, Process Development, Amgen, Inc.
• Maninder Hora, Ph.D., Vice President, Process Development, PDL BioPharma, Inc.
• Günter Jagschies, Ph.D., Director R&D, Customer Applications, Protein Separation, GE Healthcare Bio-Sciences, Sweden
• Ellen L. McCormick, Director, BioProcess R&D, Pfizer Global Biologics, Pfizer, Inc
• R. Andrew Ramelmeier, Ph.D., Vice President, Manufacturing and Process Development, BioMarin Pharmaceutical, Inc.
• Tom Ransohoff, Senior Consultant, BioProcess Technology Consultants, Inc.
• David H. Reifsnyder, Ph.D., Principal Scientist, Process Development-Late Stage Purification, Genentech, Inc.
• Abhinav Shukla, Ph.D., Associate Director Manufacturing Sciences, Bristol-Myers Squibb

Track 3: Cell Culture & Upstream Processing

• Timothy S. Charlebois, Ph.D., Director, Cell & Molecular Sciences, Wyeth BioPharma
• Laurel Donahue-Hjelle, Ph.D., Director of Cell Line Development, Invitrogen Corporation
• Kevin J. Kayser, Ph.D., R & D Manager, Cell Line Engineering, SAFC Biosciences
• Dennis M. Kraichely, Ph.D., Principal Research Scientist, Expression Technologies, Centocor, Inc.
• Suzanne Kuo, Ph.D., Senior Engineer, Late Stage Cell Culture Process Development, Genentech, Inc.
• John Mott, Ph.D., Director, Bioprocess R&D, Cell Line Development, Pfizer Global Biologics
• Charles Sardonini, Ph.D., Associate Director, Process Engineering/Development, Genzyme Corporation
• Thomas Seewoester, Ph.D., Director, Process Development, Amgen Inc.
• Gary Welch, Director, Process Development, Abbott Bioresearch Center

Track 4: Recovery & Purification

• Edward Cole, Ph.D., Senior Vice President, Protein Development, Genzyme Corporation
• Chris Dowd, Ph.D., Senior Engineer, Late Stage Purification, Genentech, Inc.
• Adam Goldstein, M.S., Senior Manager, Oceanside Clinical Operations, Genentech, Inc.
• Uwe Gottschalk, Ph.D., Vice President, Purification Technology, Sartorius Stedim Biotech, Germany
• Brian R. Hubbard, Ph.D., Scientific Executive Director, Process and Analytical Sciences, Amgen Inc.
• David W. Kahn, Ph.D., Director, Late-Stage Purification Development, Human Genome Sciences, Inc.
• Charles Schmelzer, Ph.D., Senior Scientist, Late Stage Purification, Genentech, Inc.
• Michiel E. Ultee, Ph.D., Senior Director, Process Sciences, Laureate Pharma, Inc.
• Peter W. Wojciechowski, Director, Process and Analytical CMC, Johnson and Johnson Regenerative Therapeutics
• Paul Wu, Ph.D., Manager of Protein Isolation, Bayer Healthcare